|Day Low/High||1.62 / 1.65|
|52 Wk Low/High||1.00 / 2.92|
CAMBRIDGE, Mass., May 16, 2019 /PRNewswire/ -- Infinity Pharmaceuticals, Inc.
-- MARIO-275 Phase 2 Study in I/O Naïve Urothelial Cancer Patients on Track to Initiate in 2Q19 --
CAMBRIDGE, Mass., April 30, 2019 /PRNewswire/ -- Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., April 2, 2019 /PRNewswire/ -- Infinity Pharmaceuticals, Inc.
-- Copiktra™ Royalty Monetization for $30M in Gross Proceeds --
- Infinity Enters into Master Clinical Supply Agreement with Roche to Provide atezolizumab (Tecentriq®) for MARIO-3 -
CAMBRIDGE, Mass., March 7, 2019 /PRNewswire/ -- Infinity Pharmaceuticals, Inc.
- Infinity Retains $22.5 Million in Gross Proceeds After Sharing with Takeda -
Bristol-Myers Squibb Company (NYSE: BMY) and Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced a clinical trial collaboration to evaluate Bristol-Myers Squibb's Opdivo in combination with Infinity's IPI-549 in patients with advanced urothelial...
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, and Infinity Pharmaceuticals, Inc.
Today Serametrix Corporation announced that Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) has enrolled the first patient in a clinical trial in which the Serametrix MDSC Assay is being used to pre-select patients having high baseline blood levels of...
Investors in Infinity Pharmaceuticals Inc saw new options begin trading this week, for the July 2018 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 211 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
Investors in Infinity Pharmaceuticals Inc saw new options become available this week, for the December 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the INFI options chain for the new December 15th contracts and identified one put and one call contract of particular interest.
Until market conditions shift, I won't be making any sizable buys.
The most recent short interest data has been released for the 04/13/2017 settlement date, which shows a 591,228 share decrease in total short interest for Infinity Pharmaceuticals Inc , to 2,765,545, a decrease of 17.61% since 03/31/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
Insiders at Infinity Pharmaceuticals and Och-Ziff Capital Management Group -- among other companies -- have been scooping up shares of their own stock lately.
Insiders at these companies -- including Wynn Resorts and Virtu Financial -- have been scooping up shares of their own stock lately.
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Infinity Pharmaceuticals Inc , where a total volume of 7,196 contracts has been traded thus far today, a contract volume which is representative of approximately 719,600 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 130.3% of INFI's average daily trading volume over the past month, of 552,295 shares.
Bristol-Myers Squibb Company (NYSE: BMY) and Infinity Pharmaceuticals, Inc.
Verastem, Inc. (NASDAQ:VSTM) and Infinity Pharmaceuticals, Inc.
The most recent short interest data has been released for the 10/14/2016 settlement date, which shows a 408,920 share increase in total short interest for Infinity Pharmaceuticals Inc , to 2,067,803, an increase of 24.65% since 09/30/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
Infinity Pharmaceuticals (INFI) said preliminary results from its IPI-549 drug trial showed that the cancer treatment can reverse tumor resistance to checkpoint inhibitors.
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Trade-Ideas LLC identified Infinity Pharmaceuticals (INFI) as a weak on high relative volume candidate
Analysts cut valuation estimates for Infinity Pharmaceuticals after a disappointing drug study.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.